Stilla Technologies

What Stilla Technologies does

Stilla Technologies was a Paris-based (Villejuif, France) biotechnology company founded in 2013 that developed digital PCR (dPCR) platforms for absolute nucleic acid quantification. The company's core technology addressed key limitations of traditional quantitative PCR (qPCR), including the need for standard curves, limited precision at low copy numbers, and constrained multiplexing, by partitioning samples into thousands of individual reactions for absolute target counting. Its products served life science research institutions, pharmaceutical companies (with applications in cell therapy, oncology, and infectious disease testing), and clinical diagnostics laboratories requiring highly sensitive and precise nucleic acid measurement.

The product portfolio centered on three platforms: the naica System (an all-in-one dPCR workflow integrating sample-to-result), the legacy Nio System, and the next-generation Nio+ instrument launched in 2024 with high multiplexing capabilities enabling multi-target detection in a single reaction. The company held registered trademarks for "Stilla," "naica," and "Nio," and its underlying technology was supported by an installed base cited in over 12,000 peer-reviewed publications. Revenue derived from instrument sales combined with recurring consumables including proprietary cartridges, supermixes, reagents, and assay kits, distributed through direct enterprise sales and, post-acquisition, Bio-Rad's global commercial channels.

Stilla pursued a sales-led go-to-market targeting academic research, pharmaceutical, and clinical diagnostics customers, raising approximately €57.8 million in cumulative venture funding across rounds led by investors including Casdin Capital, the European Investment Bank, Tusholdings, Illumina Ventures, Kurma Partners, and CLIIF. In February 2025 the company was acquired by Bio-Rad Laboratories (NYSE: BIO) with the transaction completing in June 2025; following the deal, Stilla's platforms are integrated into Bio-Rad's Droplet Digital PCR portfolio alongside the expanded QX ddPCR instrument family, and Bio-Rad has guided that the acquisition will be accretive by mid-2026, six to 12 months earlier than initially anticipated.

Name

Stilla Technologies

Website

https://stillatechnologies.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

51–100 employees

Short description

Stilla Technologies was a Paris-based digital PCR company developing all-in-one nucleic acid quantification platforms (naica, Nio, Nio+) for life science research, pharmaceutical, and clinical diagnostics customers, acquired by Bio-Rad Laboratories in 2025.

Ownership category

akta.pro rank

Product category

Digital PCR Instruments and Molecular Diagnostics Platforms

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)

Keywords

• Digital PCR systems
• Molecular diagnostics instruments
• Nucleic acid quantification
• PCR consumables reagents
• Life science research

Headquarters

HQ city

Villejuif

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Digital PCR Instruments and Consumables: Stilla Technologies generated revenue from the sale of digital PCR instruments (Nio+, naica, Nio systems) and associated consumables including cartridges, reagents, and assays. Following acquisition by Bio-Rad in 2025, this revenue stream is now integrated into Bio-Rad's Life Science segment which reported Q4 2025 revenue of $267.9 million for the Life Science segment.
2. Digital PCR Reagents and Assays: Sale of specialized reagents, supermixes, and assay kits designed for use with Stilla's digital PCR platforms. These consumable products provide recurring revenue tied to instrument utilization.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Stilla Technologies develops and manufactures digital PCR (dPCR) instruments—the naica System, Nio System, and the next-generation Nio+—along with associated consumables including cartridges, reagents, supermixes, and assay kits. These platforms deliver absolute nucleic acid quantification without standard curves and support high-multiplexing detection for molecular diagnostics, oncology, infectious disease testing, and cell therapy applications. Following Bio-Rad Laboratories' acquisition completed in June 2025, the products are sold through Bio-Rad's global commercial organization.

Product overview

Stilla Technologies developed a portfolio of all-in-one digital PCR platforms, including the naica System, Nio System, and the newer Nio+ instrument. The Nio+ represents the next-generation platform featuring high multiplexing capabilities for enhanced molecular diagnostics applications. The company was acquired by Bio-Rad Laboratories in February 2025, with the acquisition completed in June 2025, integrating Stilla's digital PCR technology into Bio-Rad's Droplet Digital PCR (ddPCR) portfolio to accelerate innovation in molecular diagnostics for infectious disease testing, oncology, and cell therapy applications.

Differentiator

Problem solved

Functional benefit

Brands

• naica System: Legacy digital PCR system now part of Bio-Rad's portfolio following acquisition
• Nio System

Products and services

• naica System All-in-one digital PCR platform providing absolute quantification without the need for standard curves, with seamless workflow integration from sample to results. Targeted at molecular diagnostics applications including infectious disease testing, oncology, and liquid biopsy for research and clinical laboratories.
• Nio System Legacy digital PCR system originally developed by Stilla Technologies and now maintained as part of Bio-Rad's portfolio. Provides digital PCR capabilities for research and clinical applications.
• Nio+ Instrument Advanced next-generation digital PCR instrument featuring high multiplexing capabilities for multi-target detection in a single reaction. Designed for molecular diagnostics applications including infectious disease testing, oncology research, and cell therapy development for pharmaceutical companies, research institutions, and clinical diagnostics laboratories.
• Digital PCR Reagents and Consumables Specialized reagents, supermixes, droplet generation oil, cartridges, gaskets, plates, seals, and assay kits designed for use with Stilla's digital PCR platforms (naica and Nio systems). These consumables generate recurring revenue tied to instrument utilization and are used by life science researchers and clinical diagnostics laboratories.

Quantifiable outcome

• Droplet Digital PCR business showed strong growth in Q4 2025 following Stilla acquisition (Bio-Rad Q4 2025 earnings)
• +1 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Bio-Rad LaboratoriescoreStrategic or Co-development Partner · 1 February 2025Bio-Rad Laboratories acquired Stilla Technologies in February 2025 to integrate Stilla's all-in-one digital PCR platforms (naica and Nio systems) into Bio-Rad's portfolio for accelerated innovation in molecular diagnostics for infectious disease testing, oncology, and cell therapy applications. Acquisition completed June 2025.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Bio-Rad Laboratories: Parent company and the dominant player in digital PCR via its QX Droplet Digital PCR (ddPCR) platform. Acquired Stilla in 2025 and now distributes both Stilla's naica/Nio+ systems and its own QX ddPCR instruments, making it the most direct strategic peer.
• Thermo Fisher Scientific: Global life sciences incumbent offering the QuantStudio Absolute Q Digital PCR System alongside a broad molecular biology portfolio. Competes with Stilla in research and pharma labs and has substantially greater commercial reach.
• Roche Diagnostics: Major diagnostics player with digital PCR investments and a broad molecular diagnostics menu spanning infectious disease and oncology — the same high-value dPCR use cases Stilla targeted.
• Becton, Dickinson and Company (BD): Large diagnostics and life sciences company with molecular testing solutions including digital PCR-adjacent workflows in infectious disease and oncology — overlapping end-user segments with Stilla's clinical customers.
• PerkinElmer / Revvity: Offers reagents, consumables, and instruments used across genomic and molecular workflows, competing with Stilla for pharma and translational research budgets in nucleic acid quantification.
• Danaher (Cepheid, Beckman Coulter): Multi-brand life sciences conglomerate whose subsidiaries compete across molecular diagnostics and lab instrumentation; Cepheid's GeneXpert and adjacent platforms address overlapping clinical molecular use cases as Stilla's naica.

Direct peers

• QIAGEN: Direct digital PCR competitor through its QIAcuity dPCR platform, serving molecular diagnostics, research, and pharma customers with a fully integrated nanoplate-based system that competes head-to-head with Stilla's naica and Nio+.
• Standard BioTools: Operates the Biomark HD high-throughput real-time PCR system and microfluidics-based molecular workflows, competing for high-multiplex and translational research budgets that overlap with Stilla's Nio+ positioning.
• Promega Corporation: Provides nucleic acid analysis reagents and instruments, including quantification and detection solutions for research and clinical labs — overlapping product categories with Stilla's reagent/consumables line.

Emerging players

• Takara Bio: Specialized in molecular biology reagents and instrumentation, including digital PCR-adjacent technologies and gene therapy QC workflows that overlap with Stilla's cell therapy and gene expression use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/stillatech
• LinkedInlinkedin.com/company/stilla-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stilla Technologies